The Pharma Data

JANUARY 5, 2021

(Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. The presentation will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. An archived replay of the webcast will be available for at least 30 days following the presentation. About Relay Therapeutics.

Small Molecule 52

Small Molecule Therapies Drugs 52

Creative Biolabs

JUNE 29, 2023

At present, a large number of G protein-coupled receptor-targeted drugs have been marketed, and a large number of drugs are under development. While the development of small molecule drugs targeting GPCRs, the development of monoclonal antibody drugs has also received great attention.

Therapies 52

Therapies Small Molecule Drugs Drug Development 52

The Pharma Data

NOVEMBER 18, 2020

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort. These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Presentation number: 397P / Poster: ID 680.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? We have already applied this approach to several important tumour targets where enhancements in TCR-T therapy may lead to important gains in clinical benefit, including mutated KRAS, NY-ESO, and HPV E7 antigens.

Immune Response 106

Immune Response Therapies Vaccine Small Molecule 106

DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. An example is the collaboration between Novartis and the University of Oxford to develop a gene therapy for spinal muscular atrophy, a rare genetic disease.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

The Pharma Data

OCTOBER 26, 2020

Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH Capital Partners 2020 MedTech Innovation Forum on Wednesday, October 28, 2020. SAN JOSE, Calif. ,

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

MAY 16, 2022

AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022, in San Diego and virtually. “We are proud to present data on a range of digestive conditions across our portfolio and pipeline. .

Disease 40

Disease Small Molecule Treatment Trials 40

The Pharma Data

SEPTEMBER 28, 2020

The product, known as INNA-051, is a synthetic small molecule therapy, self-administered once or twice weekly with an almost immediate effect. Research drawn from an animal-based clinical study led by Public Health England demonstrated the spray generated a reduction of up to 96% in viral replication of the novel coronavirus.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

LifeSciVC

DECEMBER 6, 2022

Darnell’s 2002 paper Transcription Factors as Targets for Cancer Therapy , in which he wrote: “A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. We are rapidly advancing the chemistry required modulate its activity.

Small Molecule 40

Small Molecule DNA Regulations Science 40

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. With the introduction of small-molecule medication, we open a new chapter in the fight against neurodegenerative diseases and have the chance to improve the lives of millions of patients drastically.”.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

JANUARY 10, 2021

IDE397 program update to be presented at the 39th Annual J.P. “The IDE397 IND submission is an important milestone for IDEAYA as we advance our broader synthetic lethality pipeline of potential first-in-class therapies. IDEAYA’s presentation for the 39 th Annual J.P. SOUTH SAN FRANCISCO, Calif. ,

FDA 52

FDA Small Molecule Clinical Trials Therapies 52

The Pharma Data

JUNE 14, 2023

Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition. With our oncology strategy, we are dedicated to accelerating the research and development of novel cancer therapies that have the potential to make a meaningful difference in the lives of patients.”

Licensing 40

Licensing Licensing Small Molecule Science 40

Conversations in Drug Development Trends

MAY 30, 2024

This research community is exploring diverse therapeutic avenues and creative thinking, including gene therapies, cell therapies, immunotherapies, novel drug candidates, and the repurposing of drugs from other indications.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Pharma Data

JANUARY 13, 2021

Knopp expects to present results of the trial at a forthcoming medical meeting. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. The trial was conducted at 28 U.S. study centers. Please visit www.knoppbio.com. ABOUT ORAL DEXPRAMIPEXOLE.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

MARCH 23, 2022

“These positive results demonstrate that etrasimod, if approved, could be a potential breakthrough option for patients with ulcerative colitis who aren’t able to experience improvement on current therapies,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development.

Trials 52

Trials Small Molecule Biosimilars Therapies 52

LifeSciVC

MARCH 1, 2023

Importantly, they also pointed to something that we at HotSpot Therapeutics and a small group of other researchers and companies recognized several years ago – that scientific advances have made this attractive, but once considered ‘undruggable,’ target druggable.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

Agency IQ

NOVEMBER 3, 2023

regulatory landscape for probiotics and other microbiome-based therapies Probiotics, a type of microbiome-based therapy containing live micro-organisms, are broadly available on drug store and grocery store shelves, but the regulatory classifications for products containing the same micro-organism can differ dramatically.

Therapies 40

Therapies Science FDA Production 40

Advarra

FEBRUARY 24, 2023

How do you know your experimental therapy is working? How do you strategically plan your therapy and research objectives to improve the chances you will satisfy what the regulators are looking for and ultimately get your therapy approved for marketing?

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

LifeSciVC

APRIL 2, 2024

The science presents an opportunity and a challenge for us at Sionna. We are confident that there is room for improvement over existing cystic fibrosis (CF) therapies because we have not yet achieved fully normalized function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

Science 68

Science Small Molecule International Clinical Development 68

Drug Target Review

NOVEMBER 22, 2023

Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

KIF1A

MAY 9, 2023

KIF1A.ORG’s 23rd Research Roundtable meeting, “Structure to Patient Perspective: Vision Loss in KAND” was presented by KIF1A.ORG’s Dr. Dylan Verden. Furthermore, both small molecule and gene therapy treatments that increase BDNF levels reduced neurodegeneration in these models.

Research 52

Research Small Molecule Treatment Science 52

The Pharma Data

MARCH 18, 2022

They control the iCAP system by giving it an external cue – a small molecule called IPTG – that allows for programmable and dynamic alteration of the E. Using Bacteria For Therapy. The cloaking approach presented in this study may address this critical issue.” .” An Effective On/Off Switch.

Engineering 52

Engineering Drugs Small Molecule Therapies 52

The Pharma Data

AUGUST 30, 2021

The head-to-head study was designed to directly compare the efficacy of abrocitinib 200mg versus dupilumab 300mg, in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD). Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. About Abrocitinib.

Small Molecule 52

Small Molecule Trials Treatment FDA 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. SUZHOU, China and ROCKVILLE, Md. , 29, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), Aguilar, A.; Bernard, D.;

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

JANUARY 18, 2021

A live webcast of this presentation will be available for registered participants at: [link]. Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

The Pharma Data

OCTOBER 25, 2020

Astellas Pharma , FibroGen and AstraZeneca presented 42 abstracts about Roxadustat at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined congress. The FibroGen and AstraZeneca presentations focus on efficacy and safety data from pooled analyses from several Phase III trial of patients on and not on dialysis.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Drug Target Review

JULY 12, 2023

We also leverage existing clinical gene expression data from different subsets of molecularly profiled cancer patients, who differ in a certain aspect of disease or response to a particular therapy. With this drop off, the goal is to reach a near-zero drug trough before the 24-hour mark.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

The Pharma Data

MARCH 29, 2022

The global Phase 3 multi-center, randomized, double-blind, placebo-controlled study enrolled 433 UC patients who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Full results from the studies will be submitted for future scientific publication and presentation.

Trials 52

Trials Small Molecule Disease Biosimilars 52

The Pharma Data

NOVEMBER 23, 2020

His most recent position was at Amgen as Director Global Business Development – Transactions, a position he assumed in August 2019 following the acquisition of Nuevolution, a Danish small molecule development company, at which he led the commercial and business activities as Chief Business Officer.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

Elrig

JUNE 4, 2024

What drew you to present at ELRIG? The focus used to be more on small molecules, but we’re now starting to see antibody and cell therapeutics. Explore cutting-edge research in therapeutic areas, including mechanisms of aging and cell & gene therapy. It is the Flagship Drug Discovery conference in the UK.

Small Molecule 52

Small Molecule Science Drugs Research 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

KIF1A

JUNE 30, 2023

This program helped obtain wheelchairs for 2 KAND patients and a vibration therapy plate to help one patient with their circulation. With these models established, we are preparing to test our first batch of small molecules drugs later this year! Look for the student presentations at the KAND conference this August!

Small Molecule 52

Small Molecule Treatment Doctors Research 52

The Pharma Data

FEBRUARY 25, 2022

The company anticipates submitting study results for presentation at an upcoming medical congress. Our differentiated R&D approach resulted in one of the broadest pipelines in the industry, where we purposefully match molecules to diseases where we believe they can make the biggest difference.

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

The Pharma Data

FEBRUARY 18, 2022

At a high-level meeting at BioNTech’s new manufacturing facility in Marburg and at the invitation of kENUP Foundation, the company presented the container solution named “BioNTainer” to key partners.

Vaccine 40

Vaccine Production Small Molecule Compliance 40

The Pharma Data

MARCH 23, 2022

In fact, antiviral therapies designed to treat viruses such as hepatitis C (Sofosbuvir/SOVALDI) work by blocking viral polymerase. “This presents additional hurdles for polymerase,” says Fang. . “To target the virus, we need to know which tools it uses,” says LJI President and CEO Erica Ollmann Saphire, Ph.D.,

Virus 52

Virus Small Molecule Protein Production Research 52